Related Experiment Video

Updated: Aug 15, 2026

In Vitro Model for Studying Differentiation and Changes of Multi-Omics on Murine Airway Epithelial Cells Stimulated with Cigarette Smoke Extract
09:07

In Vitro Model for Studying Differentiation and Changes of Multi-Omics on Murine Airway Epithelial Cells Stimulated with Cigarette Smoke Extract

Published on: July 12, 2024

Decreased expression of TGF-beta type II receptor in bronchial glands of smokers with COPD

S Baraldo1, E Bazzan, G Turato

  • 1Department of Cardio-Thoracic and Vascular Sciences, Section of Respiratory Diseases, University of Padova, Italy.

Thorax
|October 18, 2005
PubMed
Abstract

Insights

In smokers with chronic obstructive pulmonary disease (COPD), reduced transforming growth factor-beta1 type II receptor (TGF-beta RII) in bronchial glands correlates with larger gland size. This suggests TGF-beta signaling absence may drive mucus hypersecretion in COPD.

Area of Science:

  • Pulmonary Medicine
  • Cell Biology
  • Molecular Biology

Background:

  • The role of transforming growth factor-beta1 (TGF-beta1) in chronic obstructive pulmonary disease (COPD) is debated.
  • TGF-beta1 may protect against mucus hypersecretion by downregulating mucin production.

Purpose of the Study:

  • Investigate the expression of TGF-beta1 and its type II receptor (TGF-beta RII) in the bronchial glands of smokers with COPD.
  • Determine the relationship between TGF-beta RII expression and bronchial gland size in COPD.

Main Methods:

  • Immunohistochemical examination of TGF-beta1 and TGF-beta RII expression in bronchial glands.
  • Comparison between 12 smokers with COPD and 12 smokers with normal lung function.

Main Results:

  • TGF-beta1 expression was similar between groups.
  • TGF-beta RII expression was significantly lower in smokers with COPD (p=0.004).
  • TGF-beta RII expression inversely correlated with Reid's index (gland size) (p=0.02, r=-0.50).

Conclusions:

  • Smokers with COPD exhibit decreased TGF-beta RII expression in bronchial glands, linked to gland enlargement.
  • Reduced TGF-beta signaling may lead to structural changes in bronchial glands, potentially promoting mucus hypersecretion in COPD.

More Related Videos

Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures08:42

Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures

Published on: May 26, 2023

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...